Synaptogenix (SNPX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $2.31 to $2.44
• 50-Day Range: $2.01 to $2.99
• 52-Week Range: $1.84 to $5.38
• Volume: 11,055 shs
• Average Volume: 25,954 shs
• Market Capitalization: $3.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Synaptogenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Synaptogenix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently decreased by 88.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently decreased by 88.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.44

News Sentiment

Synaptogenix has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Synaptogenix this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.73% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

Only 10.34% of the stock of Synaptogenix is held by institutions.

SNPX Stock Analysis - Frequently Asked Questions

How have SNPX shares performed this year?

Synaptogenix's stock was trading at $3.47 at the beginning of 2025. Since then, SNPX stock has decreased by 31.4% and is now trading at $2.38.
View the best growth stocks for 2025 here.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:SNPX) posted its quarterly earnings data on Thursday, March, 27th. The company reported ($4.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.06) by $2.30.

When did Synaptogenix's stock split?

Shares of Synaptogenix reverse split on the morning of Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Synaptogenix?

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Synaptogenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 4/29/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.synaptogen.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +488.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($10.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.14%
• Return on Assets: -29.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 65.34
• Quick Ratio: 65.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.27 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 1,390,000
• Free Float: 1,319,000
• Market Cap: $3.31 million
• Optionable: Not Optionable
• Beta: 1.07